Fact File
In 2012, WHO reported a gradual increase in resistance to HIV drugs, albeit not reaching critical levels. Since then, further increases in resistance to first-line treatment drugs were reported, which might require using more expensive drugs in the near future.\
In 2013, there were about 480 000 new cases of multidrug-resistant tuberculosis (MDR-TB). Extensively drug-resistant tuberculosis (XDR-TB) has been identified in 100 countries. MDR-TB requires treatment courses that are much longer and less effective than those for non-resistant TB.
In parts of the Greater Mekong sub region, resistance to the best available treatment for falciparum malaria, artemisinin-based combination therapies (ACTs), has been detected. Spread or emergence of multidrug resistance, including resistance to ACTs, in other regions could jeopardize important recent gains in control of the disease.
There are high proportions of antibiotic resistance in bacteria that cause common infections (e.g. urinary tract infections, pneumonia, bloodstream infections) in all regions of the world. A high percentage of hospital-acquired infections are caused by highly resistant bacteria such as methicillin-resistant Staphylococcus aureus(MRSA) or multidrug-resistant Gram-negative bacteria.
Main causes of drug resistance in developing world
With the menace of antimicrobial resistance continuing to sail across the global health system, this month we set our eyes into understanding some of the sector specific causes of drug resistance in sub Saharan Africa.
Selection of resistant microorganisms is exacerbated by inappropriate use of antimicrobials. Sometimes healthcare providers will prescribe antimicrobials inappropriately, wishing to placate an insistent patient who has a viral infection or an as-yet undiagnosed condition. This may be prompted by the heavy patient load that awaits the providers on day to day basis. Poor prescription is a major contributor to the menace of drug resistance.
In our previous editorial focuses we have mentioned the absence of resources as a unique factor in our health system. The absence of diagnostic equipment including the lack of service of the existing equipment results in errors in telling out what the patient is suffering from. Assumed and erroneous prescriptions have their trace here and in general perspective it results in drug resistant.
- Minimal regulations and improper enforcement of the existing drug regulations
In Africa and to say Kenya and Tanzania for example the regulations on counter purchase of drugs are absent. The patients thus use their symptoms to seek for drugs and without proper prescriptions they use them. This is a major factor fueling the spread of drug resistance since there is little follow up on proper adherence to prescription as well as the chance of error in using symptoms to guess one’s illness.
Critically ill patients are more susceptible to infections and, thus, often require the aid of antimicrobials. However, the heavier use of antimicrobials in these patients can worsen the problem by selecting for antimicrobial-resistant microorganisms. The extensive use of antimicrobials and close contact among sick patients creates a fertile environment for the spread of antimicrobial-resistant germs. Besides the lack of proper infection control measures within the hospital set up leads to the spread of this infections. There is thus need to adopt preventive measures and have proper guideline to the use of the drugs and infection control.
- Lack of alternative treatment options
This is a factor that speaks to the research arm of the healt6h system calling on it and the need to continually develop alternative solutions treatment plans and options for the various illnesses. This is key to ensuring that in the event of a noted resistance there is a tested alternative. Absence of alternative is a major cause of the resulting morbidity and mortality from drug resistance cases.
It’s a global threat, requiring a global solution but it is much more about the action taken by the local health system to address the sector specific and controllable valuables in drug resistance.
Back to top
|